

Histone demethylase JMJD2C: epigenetic regulators in tumors

Chengcheng Zhang^{1,2}, Zhongqi Wang², Qing Ji¹ and Qi Li¹

¹Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

²Department of Medical Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

Correspondence to: Qing Ji, email: ttt99118@hotmail.com
Qi Li, email: Lzwf@hotmail.com

Keywords: histone demethylase, JMJD2C, epigenetic regulation, tumor

Received: May 16, 2017

Accepted: June 28, 2017

Published: July 12, 2017

Copyright: Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Histone methylation is one of the major epigenetic modifications, and various histone methylases and demethylases participate in the epigenetic regulating. JMJD2C has been recently identified as one of the histone lysine demethylases. As one member of the Jumonji-C histone demethylase family, JMJD2C has the ability to demethylate tri- or di-methylated histone 3 and 2 in either K9 (lysine residue 9) or K36 (lysine residue 36) sites by an oxidative reaction, thereby affecting heterochromatin formation, genomic imprinting, X-chromosome inactivation, and transcriptional regulation of genes. JMJD2C was firstly found to involve in embryonic development and stem cell regulation. Afterwards, aberrant status of JMJD2C histone methylation was observed during the formation and development of various tumors, and it has been reported to play crucial roles in the progression of breast cancer, prostate carcinomas, osteosarcoma, blood neoplasms and so on, indicating that JMJD2C represents a promising anti-cancer target. In this review, we will focus on the research progress and prospect of JMJD2C in tumors, and provide abundant evidence for the functional application and therapeutic potential of targeting JMJD2C in tumors.

INTRODUCTION

JMJD2C (Jumonji domain 2C), also well known as KDM4C (Histone lysine demethylases 4C), is mapped to human chromosome 9p24.1, encoded a protein with 1054 amino acid residues. It is one member of Jumonji domain-2 families and encodes a protein with one JmjN domain (N-terminal Jumonji N domain), one JmjC domain, two PHD (C-terminal plant homeodomain) and two Tudor domains which mostly localized in the nucleus (Figure 1) [1, 2]. The crystal structure of the catalytic domains and tudor domains of human JMJD2C characterized by X-RAY diffraction was shown in Figure 2 [3–5].

JMJD2C has been proved to be a demethylase for H3K9 methylation, in the manner of catalyzing the demethylation of H3K9me3/me2 (the known repressive markers of gene regulation), a histone mark found in heterochromatin associated with euchromatic

transcriptional silencing and heterochromatin formation [6]. Besides, JMJD2C also catalyzes the demethylation of H3K36me3 (the second methylated histone substrate of JMJD2C) [3]. In addition, JMJD2C has been reported to demethylates H3K9me3 by two sequential reactions: removing the methyl groups from methylated lysines of histone H3 and disconnecting from the nitrogen center [7].

JMJD2C has been shown to have a variety of function both in normal biology and in tumorigenesis. Early in year 2007, JMJD2C was firstly found to involve in embryonic development and stem cell regulation [8–11], and it acted as a positive regulator for Nanog (a key transcription factor for self-renewal in embryonic stem cells) by reversing the H3K9Me3 marks at the Nanog promoter region and consequently prevents transcriptional repressors HP1 (heterochromatin protein 1) and KAP1 (Krüppel-associated box (KRAB) domain-associated protein 1) from binding. JMJD2C was necessary for self-renewal of ESCs and induced

pluripotent stem cell generation by assisting PRC2 (Polycomb repressive complex 2) in transcriptional repression [12]. JMJD2C was also found to regulate neural stem cell differentiation by controlling the gene-specific methylation of H3K9 and H3K36 on neurotrophic BDNF versus astroglial GFAP genes [13]. However, more and more evidences have also demonstrated that JMJD2C play an important role in the tumorigenic processes. JMJD2C could regulate androgen receptor-dependent gene expression, embryonic stem-cell self-renewal, and tumorigenesis [14]. Overexpression of JMJD2C could up-regulate the expression of oncogene Mdm2 (murine double minute 2) and lead to the decreased expression of tumor suppressor gene p53 [15]. Notably, as the downstream targets of BMP4, bFGF and VEGF, JMJD2C activated VE-cadherin expression and allowed the cells to form stable adherens junctions and functional vascular networks [16, 17]. All the reported results demonstrated that JMJD2C is a candidate oncogene.

In this review, we will focus on the research advance and future prospect of oncogene JMJD2C in tumors, and

provide enough evidence for functional application and therapeutic potential of targeting JMJD2C in tumors.

ORIGINS AND PROPERTIES OF JMJD2C

It is well known that, histone modifications can regulate gene expression by establishing global chromatin environments [18, 19, 20], and these epigenetic changes in chromatin environments are the underlying causes of tumors development. The amino-terminal tails of histone are subjected to numerous reversible posttranslational modifications, such as phosphorylation [21], acetylation [22], ubiquitination [23], sumoylation [24], ADP ribosylation [25], and methylation [26, 27]. Among them, methylation, can specifically modify chromatin structure and regulate gene expression [28, 29]. Histone methylation was considered as a stable modification until the discovery of lysine-specific demethylase 1 (LSD1) in 2004, which was the firstly identified histone demethylase. The discovery of LSD1 demonstrated that, histone methylation was reversible and dynamically regulated [30–33].




Figure 1: Schematic summary of JMJD2C domain structure. It contains one JmjN domain (N-terminal Jumonji N domain), one JmjC domain, two PHD (C-terminal plant homeodomain) and two Tudor domains that recognize and bind methylated histones.




Figure 2: Crystal structure of human JMJD2C protein characterized by X-RAY diffraction. (A) The tudor domains that recognize and bind methylated histones, and the catalytic domains are marked in the schematic image of JMJD2C crystal structures. (B) The functional molecules including NOG (N-Oxalylglycine), Zn (Zinc Ion) and Ni (Nickel (II) Ion) are presented in the precise image of JMJD2C crystal structures.

Table 1: Biological function of JMJD2C in tumors

Tumor types	Functions of JMJD2C	References
	Metabolic reprogramming	[39]
Breast cancer	Tumor cell growth and proliferation	[39, 58, 59]
	Lung metastasis	[39]
	Cellular transformation	[58, 59]
	DNA damage and repair	[55, 56, 57]
Prostate cancer	Tumor growth, proliferation and metastasis	[64, 65]
Colon cancer	Tumor growth and proliferation	[79, 80]
Osteosarcoma	Tumor proliferation, migration and invasion	[72]
Gastric cancer	Tumor growth, invasion and metastasis	[81]
Esophageal squamous cancer	Tumor cell growth	[45]
Sarcomas/Leukemias/Gliomas	Cancer development	[75, 76, 77]
Primary mediastinal B-cell lymphoma/Hodgkin lymphoma	Tumor formation	[47]
Lung cancer	Tumor cell migration and invasion	[82]

Currently, the histone demethylases are classified into two types. The first type of histone demethylase includes LSD1a (lysine specific demethylase 1) and LSD2 (lysine specific demethylase 2) [34]. The other type of histone demethylase comprises the recently discovered histone demethylases JMJD (Jumonji-C domain-containing protein) family [35]. The JMJD subfamily, comprising member A, member B, member C and member D, involves in the dynamic accommodation of histone posttranslational modification, controlling multiple biological processes such as gene transcription, epigenetic silencing, heterochromatin formation, and so on [36–38]. As we know, the lysine residues in histone tails could be mono-, di- or tri-methylated (me1/me2/me3), and the differentially methylation of lysines can result in different physiological and transcriptional outcomes. Additionally, the methylation status of H3K9 (Histone H3 lysine 9) was associated tightly with the affinity of heterochromatic proteins, which could affect the organization and stability of chromosome [39]. JMJD demethylases A, B, C and D were found to have the demethylation function on trimethylated lysines [40].

A few studies have revealed that JMJD2A is nearly comparable in the cytoplasm and nucleus, JMJD2B is mainly found in the nucleus, and JMJD2C is associated closely with the chromatin [41, 42]. More interestingly in colon cancer cells, JMJD2C appears to be co-overexpressed with JMJD2A and JMJD2B, and

JMJD2C also forms heteromers with JMJD2A, whereas JMJD2D does not have the same function as JMJD2C [43]. Additionally, JMJD2C was also found to increase MyoD (Myogenic Differentiation Antigen) transcriptional activity and facilitate skeletal muscle differentiation via inhibiting G9a-dependent MyoD degradation [44].

EPIGENETIC REGULATION OF JMJD2C IN TUMORS

Dysregulation of JMJD2C has been detected in a variety of tumors, including oesophageal squamous cell carcinoma (ESCC) [45], acute myeloid leukemia (AML) [46], primary mediastinal B cell lymphoma (PMBL), Hodgkin lymphoma (HL) [47], medulloblastoma [48], prostate cancer [49], and breast cancer [50, 39] (Table 1). In these tumors, JMJD2C could modulate the transcription factors such as androgen and estrogen receptor (AR and ER) [51], the nuclear receptor superfamily like glucocorticoid receptor (GR) and progesterone receptor (PR) [52, 53], the hypoxia-inducible factors such as HIF-1 α (Hypoxia-inducible factor-1 α) [54], and so on (Figure 3).

Breast cancer

Recent evidences have implied that alteration of JMJD2C demethylases was associated closely with the progression of breast cancer [50, 55–57]. Hong et al. [55]

has identified JMJD2C as a novel substrate for caspase-3 (cysteine-aspartic acid protease-3), and cleavage of JMJD2C by caspase-3 led to inactivation of JMJD2C demethylase activity and elevation of H3K9 methylation levels. JMJD2C could be cleaved by caspase-3 at DEVVD396G motif ((between residue 475-525), and then its demethylase activity would inactivate. In addition, D396N polymorphism (rs2296067) in the cleavage site of JMJD2C influenced the cleavage by caspase-3, following by the affection on the prognosis of breast cancer. Moreover, Hong et al. also showed that, the basal levels of DSB (double strand DNA break) repair proteins γ -H2AX increased when the activity of caspase-3 was activated. Knockdown of JMJD2C gene led to the up-regulation of basal γ -H2AX expression. and γ -H2AX together with its phosphorylated C-terminal (Sre residues 139–140, γ -H2AX) are crucial for DNA repair [56, 57]. These findings provide a novel epigenetic regulating mechanism of JMJD2C by caspase-3 cleavage, and the single nucleotide polymorphism rs2296067 of JMJD2C alters the cleavage by caspase-3 and affect the prognosis of breast cancer.

Ye et al. previously demonstrated that, JMJD2C was overexpressed in aggressive basal-like breast cancer and functioned as oncogene. Afterwards, using a large-scale data set for cancer genomics, they validated that JMJD2C was high expressed in 12.4% of basal-like tumors, and significantly higher in aggressive basal-like breast

cancer in compared with non-basal-like breast cancer. When JMJD2C was overexpressed in immortalized and nontransformed mammary epithelial MCF10A cells, it promoted growth factor-independent proliferation and anchorage-independent growth, as well as the alteration of morphogenesis in Matrigel and the mammosphere forming ability. Moreover, JMJD2C could regulate the expression of genes critical for stem cell self-renewal like NOTCH1, and was closely associated with the stem cell phenotypes in breast cancer [58]. In subsequent studies, Ye et al. also found JMJD2C served as a transforming oncogene. Knockdown of JMJD2C inhibited the proliferation of breast cancer cells *in vitro* and *in vivo*. More importantly, comparing with other members of JMJDs family, JMJD2C had the highest frequency (13.4%) of genetic alteration including mutation, homozygous deletion, high-level amplification, mRNA downregulation, and mRNA upregulation among 976 breast cancer specimens, and all the 976 Cancer Genome Atlas (TCGA) data for breast cancer were from cBio Cancer Genomics (<http://cbioportal.org>) database [59].

Strikingly, the findings by Luo et al's. suggested in breast cancer cells that [39], increased expression of JMJD2C activated the transcription of PDK1 (Pyruvate Dehydrogenase Kinase 1), LDHA (Lactate Dehydrogenase A), BNIP3 (BCL2 Interacting Protein 3) and SLC2A1 (Solute Carrier Family 2 Member 1), and all of their




Figure 3: Upstream regulating factors and downstream effectors of JMJD2C. Mdm2 (murine double minute 2), AR (androgen receptor), LSD1 (lysine-specific demethylase 1), and FGF2 (fibroblast growth factor 2).

encoded proteins [60–63] were required for metabolic reprogramming thereby stimulating HIF-1-dependent reprogramming. Moreover, knockdown of JMJD2C not only inhibited the breast tumor growth but also blocked the lung metastasis in mice. To sum up, these results reveal the important epigenetic roles of JMJD2C in breast cancer that it regulates the metabolic reprogramming and lung metastasis by coactivating HIF-1 and stimulating HIF-1-mediated transactivation (Figure 4).

Prostate cancer

Various studies have shown that, JMJD2C was overexpressed in prostate cancers and promoted abnormal activation of AR (androgen receptor) targeting genes such as kallikrein-related peptidase 2 (KLK2) and prostate-specific antigen (PSA), and both of which had the important function to cleave proteins that affecting cell proliferation and metastasis. In details, JMJD2C knockdown promoted the existence of H3K9me3 on the PSA gene, following by blocking AR-induced transcriptional activity [64].

Wissmann et al. [65] showed that, JMJD2C was found to be co-localized with AR and LSD1 in the epithelium of prostate carcinoma and normal prostate cells. For the detailed mechanism, JMJD2C, AR and LSD1 assembled on the chromatin to remove the methyl groups from mono-, di- and trimethylated H3K9. Importantly, JMJD2C specifically removed the demethylation of the trimethyl H3K9 marks and modulated the transcriptional activity of AR. Moreover, JMJD2C cooperated with LSD1 and activated AR-mediated gene expression via decreasing H3K9me3 at the promoter of AR targeting genes KLK2 and PSA. Accordingly, Hamada et al. [66] suggested that, combined application of JMJD2 inhibitors and LSD1 inhibitors would provide a novel strategy for cancer therapy.

Furthermore, Lee et al. also revealed that, in human LNCaP prostate cancer cells, the hypoxia

situation increased the levels of JMJD2C protein, and the pathological hypoxia (< 0.5% O₂) brought about the abnormal variations of epigenetic genes through modifying the quantity and activity of JMJD2C because of the existence of H3K9me3 (the substrate for JMJD2C). In details, JMJD2C has been identified as a HIF-1 α targeting gene [67]. Endogenous JMJD2C has been found to physically interact with HIF-1 α , which was involved in multi-steps of cancer progression, including cell proliferation, angiogenesis, invasion and metastasis, as well as the glucose and energy metabolism in human cancer cells [68–71]. To be concluded, these findings imply in prostate cancer that, JMJD2C interacts with HIF-1 α and promotes the transcriptional activation of PSA gene via demethylating di- and trimethylated H3K9 (Figure 4).

Osteosarcoma

Similar to above common cancers, Li et al. [72] also showed the expression of JMJD2C was significantly higher in osteosarcoma tissues in compared with adjacent non-tumor tissues. Besides, the high level of JMJD2C was strongly associated with osteosarcoma cells metastasis, indicating that JMJD2C acted as a risk factor of osteosarcoma. As far as the detailed mechanism in osteosarcoma, JMJD2C could up-regulate the expression of FGF2 (fibroblast growth factor 2) and interact with FGF2, which is a prototypic growth factor [73] and plays a promoting role in carcinogenesis [74]. The silence of JMJD2C gene significantly inhibited the osteosarcoma cell invasion and migration in MG63 cells. These results indicated that, JMJD2C could promote osteosarcoma cell proliferation, migration and invasion via interacting with FGF2.

Blood neoplasms

Co-recruitment of JMJD2C and Prmt1 (protein arginine methyltransferase 1) by MOZ (monocytic




Figure 4: JMJD2C regulates the transcription of HIF-1 target gene in hypoxic environment, and involves in cancer progression including proliferation, invasion, metastasis, and metabolic reprogramming in tumors. In hypoxia, HIF-1 α dimerizes with HIF-1 β to form active HIF-1 complex. JMJD2C interacts with HIF-1 α and promotes the transcriptional activation of HIF-1 targeting genes via demethylating di- and trimethylated H3K9. The HIF-1 targeting genes include BNIP3 (BCL2 Interacting Protein 3), PDK1 (Pyruvate Dehydrogenase Kinase 1), LDHA (Lactate Dehydrogenase A), SLC2A1 (Solute Carrier Family 2 Member 1), L1CAM (L1 Cell Adhesion Molecule), LOXL2 (Lysyl Oxidase Like 2), and PSA (prostate-specific antigen).

leukemia zinc finger protein)-TIF2 (transcriptional intermediary factor 2) and MLL (malignant lymphoma with leukemia)-GAS7 (Growth arrest-specific 7) in acute promyelocytic leukemia (APL) has implied the possible mechanism of JMJD2C in oncogenesis. Specifically, JMJD2C counteracted and removed the H3K9 trimethylation on target gene *Hoxa9*, which was critical for oncogenic transformation and self-renewal [75]. In addition, the inhibition of JMJD2C suppressed Acute Myeloid Leukemia (AML) by suppressing transcription and transformation abilities of MLL fusions and MOZ-TIF2 [76]. Agger et al. also showed that, JMJD2/KDM4 demethylases (including JMJD2C) are required for the expression of *IL3ra* (interleukin 3 receptor subunit alpha), as well as the survival of acute myeloid leukemia cells [77].

JMJD2C was considered as an oncogene due to its firstly discovered in primary Hodgkin lymphoma and mediastinal B-cell lymphoma, in which both of JMJD2C and tyrosine kinase JAK2 (Janus kinase 2) were found to have the function of epigenetic regulation. Inhibition of both JMJD2C and JAK2 could kill these lymphomas by promoting heterochromatin formation through decreasing tyrosine 41 phosphorylation and increasing lysine 9 trimethylation of histone H3. c-Myc was the major target of JAK2-mediated histone phosphorylation. When JMJD2C and JAK2 were inhibited, c-Myc was corresponding silenced, following by the c-Myc locus to adopt a repressive heterochromatic structure. Moreover, JMJD2C knockdown or JAK2 inhibition increased the recruitment of heterochromatin protein HP1 α to the c-Myc locus, as well as the increase of HP1 α protein in H3K9me₃, which is bound by HP1 α . In conclusion, JMJD2C and JAK2 cooperatively remodel the epigenome of Hodgkin lymphoma and primary mediastinal B-cell lymphoma, providing the possibility of the discovery of JAK2 and JMJD2C inhibitors for these malignant diseases [47].

Moreover, the JMJD2C gene was also found to be translocated in mucosa-associated lymphoid tissue (MALT) lymphoma and led to rearrangements of *ODZ2* (odd Oz/ten-m homolog 2), JMJD2C and *CNN3* (Calponin-3), which broadened the knowledge on the genetic heterogeneity of MALT lymphomas [78].

Other cancers

In colon cancer, Kim et al. firstly uncovered that JMJD2C was overexpressed in five colon cancer cell lines and especially associated closely with the growth of HCT-116 cells. Then they observed that transcriptional cofactor JMJD2C might form a complex with β -catenin, thereby regulating the levels of β -catenin downstream effectors, which was crucial for the advance of colon cancer. Furthermore, JMJD2C was required for efficient expression of cell cycle regulator Cyclin D1, oncogenic transcription factor FRA1 (Fos-related antigen 1), and anti-apoptotic BCL2 (B-cell lymphoma-2). These

results strongly suggested that, JMJD2C might promote the survival of colon cancer cells via BCL2-dependent mechanism, and stimulate the proliferation of colon cancer cells via up-regulating the levels of Cyclin D1 and FRA1 [79]. In addition, Kim et al. also demonstrated that, down-regulation of JMJD2C led to the increased levels of tumor suppressor p53 [80].

Xu et al. explored the expression of JMJD2C in gastric carcinoma using a retrospective cohort study for 110 gastric cancer patients. As a result, the positive expression rates of JMJD2C were significantly higher in tissues from gastric cancer patients than those in normal tissues. Besides, JMJD2C expression was positively correlated with the HIF-1 α expression. Over-expressions of JMJD2C and HIF-1 α in gastric cancer tissues were associated closely with the growth, invasion and metastasis of gastric tumor, implying that JMJD2C might be a bad prognosis marker for gastric cancer patients [81]. Recently, Li et al. also found that, JMJD2C could promote cell migration and invasion through modulating the *CUL4A* expression in lung cancer [82].

Although above reports have demonstrated the significance of JMJD2C in tumors, to be an effective therapeutic target, further studies are still needed to explore clearly the underlying mechanisms of JMJD2C in tumors.

THERAPEUTIC POTENTIAL OF JMJD2C

Since epigenetic changes are reversible, the histone demethylase JMJD2C is a promising therapeutic target for different tumors [59]. By far, several JMJD2C inhibitors have been developed. N-oxalylglycine 2 (NOG2), the amide analogue of α -ketoglutarate, has been reported to inhibit the activity of JMJD2C proteins *in vitro* [83]. Tan et al. also demonstrated the catalytic site of JMJD2C could be inhibited by the competitive antagonists of α -ketoglutarate [84], providing that JMJD2C might be a novel target for the treatment of breast cancer. Moreover, as one of the series of hydroxamate analogues designed by Hamada et al. hydroxamate analogue 8, showed 9100-fold greater JMJD2C-selectivity and 500-fold greater JMJD2C-inhibitory activity in compared with the NOG2 and other inhibitors for demethylase members [66, 85].

Additionally, Qin et al. has tested the effect of small molecule NCDM-32B, a novel inhibitor of JMJD2 demethylases, which had the function to attenuate the growth of breast cancer cells [59]. The NCDM-32B treatment inhibited the cell viability and anchored independent growth in breast cancer, and the mechanism referred to several vital signaling pathways that promote cell proliferation and transformation.

Besides, an unexpected function of JMJD2C was found in the DNA damage pathway. Radiation and chemotherapy may cause DNA damage and induce signaling pathways for apoptotic cell death. DNA repair

processes play key roles in the resistance to chemotherapy and radiation therapy, and H3K9me3 is involved in the initial processing of DNA repair [86]. The cleavage JMJD2C leads to accumulated levels of H3K9 methylation and enhanced ability of repair of DNA DSB (double-strand breaks) [87]. Thus, these patients carrying only cleavable JMJD2C are resistant to chemotherapy and radiation therapy, which should be considered seriously in clinical practice.

PERSPECTIVE

In summary, a number of evidences have suggested the association between JMJD2C protein and various tumors. Many efforts are underway or were already undertaken to add weight to prove JMJD2C protein is the indeed driver of tumorigenesis as well as to design specific JMJD2C inhibitors. Several types of JMJD2C inhibitors have been identified in the past few years, however, JMJD2C protein faces a variety of difficulties before acting as anticancer targets, and any kind of anticancer drugs require rigorous preclinical testing before practical application. For instance, mouse models should be used as invaluable tools for testing their effects *in vivo*, avoiding the side effects as few as possible [88, 89].

In any case, JMJD2C appears to be intricately interacting with tumor cells, and the understanding of how these interactions take place and how to apply them to clinical practice requires more studies. The protein-methyltransferase (PMT) inhibitors have been progressed to Phase I clinical trials [90], which arousing passions of researchers in tumor fields for targeting oncogenic transcription factors. Although targeting JMJD2C histone demethylases has not yet in the process for standard clinical application, the selective inhibitors for JMJD2C are becoming the candidate anticancer agents, which also provide the tools for exploring the biological mechanisms of JMJD2C.

Authors' contributions

Conceived and designed the review: QL and QJ. Consulted and analyzed the literature: CCZ and ZQW. Wrote the paper: CCZ and QJ.

ACKNOWLEDGMENTS AND FUNDING

This work was supported by International Cooperation Key Project of National Natural Science Foundation of China (81520108031) and National Natural Science Foundation of China (81573749, 81473478), Key project of Shanghai Municipal Science and Technology Commission (16401970500), Three year plan of action for innovation of traditional Chinese medicine in Shanghai (ZY3-CCCX-3-3012), Program of Shanghai Academic

Research Leader (16XD1403600), Program for Shanghai Outstanding Medical Academic Leader, Natural Science Foundation of Shanghai, China (16ZR1437700).

CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

REFERENCES

1. Labbe RM, Holowatyj A, Yang ZQ. Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential. *Am J Transl Res.* 2014; 6:1–15.
2. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. *Nature.* 2006; 442:307–311.
3. Hillringhaus L, Yue WW, Rose NR, Ng SS, Gileadi C, Loenarz C, Bello SH, Bray JE, Schofield CJ, Oppermann U. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. *J Biol Chem.* 2011; 286:41616–41625.
4. Wigle TJ, Swinger KK, Campbell JE, Scholle MD, Sherrill J, Admirand EA, Boriack-Sjodin PA, Kuntz KW, Chesworth R, Moyer MP, Scott MP, Copeland RA. A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. *J Biomol Screen.* 2015; 20:810–820.
5. Gehling VS, Bellon SF, Harmange JC, LeBlanc Y, Poy F, Odate S, Buker S, Lan F, Arora S, Williamson KE, Sandy P, Cummings RT, Bailey CM, et al. Identification of potent, selective KDM5 inhibitors. *Bioorg Med Chem Lett.* 2016; 26:4350–4354.
6. Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, Zhao K. Combinatorial patterns of histone acetylations and methylations in the human genome. *Nat Genet.* 2008; 40:897–903.
7. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, Shi Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. *Cell.* 2006; 125:467–481.
8. Loh YH, Zhang W, Chen X, George J, Ng HH. Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. *Genes Dev.* 2007; 21:2545–2557.
9. Tomaz RA, Harman JL, Karimlou D, Weavers L, Fritsch L, Bou-Kheir T, Bell E, Del Valle Torres I, Niakan KK, Fisher C, Joshi O, Stunnenberg HG, Curry E, et al. Jmjd2c facilitates the assembly of essential enhancer-protein complexes at the onset of embryonic stem cell differentiation. *Development.* 2017; 144: 567–579.

10. Sim YJ, Kim MS, Nayfeh A, Yun YJ, Kim SJ, Park KT, Kim CH, Kim KS. Zi Maintains a Naive Ground State in ESCs through Two Distinct Epigenetic Mechanisms. *Stem Cell Reports*. 2017; 8:1312–1328.
11. Pedersen MT, Kooistra SM, Radziszewska A, Laugesen A, Johansen JV, Hayward DG, Nilsson J, Agger K, Helin K. Continual removal of H3K9 promoter methylation by Jmjd2 demethylases is vital for ESC self-renewal and early development. *EMBO J*. 2016; 35:1550–1564.
12. Das PP, Shao Z, Beyaz S, Apostolou E, Pinello L, De Los Angeles A, O'Brien K, Atsma JM, Fujiwara Y, Nguyen M, Ljuboja D, Guo G, Woo A, et al. Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kdm4c in mouse embryonic stem cell identity. *Mol Cell*. 2014; 53:32–48.
13. Cascante A, Klum S, Biswas M, Antolin-Fontes B, Barnabé-Heider F, Hermanson O. Gene-specific methylation control of H3K9 and H3K36 on neurotrophic BDNF versus astroglial GFAP genes by KDM4A/C regulates neural stem cell differentiation. *J Mol Biol*. 2014; 426:3467–3477.
14. Burton A, Azevedo C, Andreassi C, Riccio A, Saiardi A. Inositol pyrophosphates regulate JMJD2C-dependent histone demethylation. *Proc Natl Acad Sci USA*. 2013; 110:18970–18975.
15. Ishimura A, Terashima M, Kimura H, Akagi K, Suzuki Y, Sugano S, Suzuki T. Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. *Biochem Biophys Res Commun*. 2009; 389:366–371.
16. Wu L, Wary KK, Revskoy S, Gao X, Tsang K, Komarova YA, Rehman J, Malik AB. Histone Demethylases KDM4A and KDM4C Regulate Differentiation of Embryonic Stem Cells to Endothelial Cells. *Stem Cell Reports*. 2015; 5:10–21.
17. Park C, Kim TM, Malik AB. Transcriptional regulation of endothelial cell and vascular development. *Circ Res*. 2013; 112:1380–1400.
18. Zhang LQ, Li QZ. Estimating the effects of transcription factors binding and histone modifications on gene expression levels in human cells. *Oncotarget*. 2017; 8:40090–40103. <https://doi.org/10.18632/oncotarget.16988>.
19. Nordström L, Andersson E, Kuci V, Gustavsson E, Holm K, Ringnér M, Guldberg P, Ek S. DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells. *BMC Cancer*. 2015; 15:273.
20. Su WX, Li QZ, Zuo YC, Zhang LQ. Association analysis between the distributions of histone modifications and gene expression in the human embryonic stem cell. *Gene*. 2016; 575:90–100.
21. Prusov AN, Smirnova TA, Kolomijtseva GY. Influence of chromatin structure, antibiotics, and endogenous histone methylation on phosphorylation of histones H1 and H3 in the presence of protein kinase A in rat liver nuclei *in vitro*. *Biochemistry (Mosc)*. 2013; 78:176–184.
22. Henry RA, Mancuso P, Kuo YM, Tricarico R, Tini M, Cole PA, Bellacosa A, Andrews AJ. Interaction with the DNA Repair Protein Thymine DNA Glycosylase Regulates Histone Acetylation by p300. *Biochemistry*. 2016; 55: 6766–6775.
23. Huang F, Ramakrishnan S, Pokhrel S, Pflueger C, Parnell TJ, Kasten MM, Currie SL, Bhachech N, Horikoshi M, Graves BJ, Cairns BR, Bhaskara S, Chandrasekharan MB. Interaction of the Jhd2 Histone H3 Lys-4 Demethylase with Chromatin Is Controlled by Histone H2A Surfaces and Restricted by H2B Ubiquitination. *J Biol Chem*. 2015; 290:28760–28777.
24. Yang Y, Tse AK, Li P, Ma Q, Xiang S, Nicosia SV, Seto E, Zhang X, Bai W. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. *Oncogene*. 2011; 30:2207–2218.
25. Leidecker O, Bonfiglio JJ, Colby T, Zhang Q, Atanassov I, Zaja R, Palazzo L, Stockum A, Ahel I, Matic I. Serine is a new target residue for endogenous ADP-ribosylation on histones. *Nat Chem Biol*. 2016; 12:998–1000.
26. Burgos ES, Wilczek C, Onikubo T, Bonanno JB, Jansong J, Reimer U, Shechter D. Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase. *J Biol Chem*. 2015; 290:9674–9689.
27. Messier TL, Gordon JA, Boyd JR, Tye CE, Browne G, Stein JL, Lian JB, Stein GS. Histone H3 lysine 4 acetylation and methylation dynamics define breast cancer subtypes. *Oncotarget*. 2016; 7:5094–5109. <https://doi.org/10.18632/oncotarget.6922>.
28. Kouzarides T. Chromatin modifications and their function. *Cell*. 2007; 128:693–705.
29. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. *Cell*. 2012; 150:12–27.
30. Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. JHDM2A, a JmJC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. *Cell*. 2006; 125:483–495.
31. Trewick SC, McLaughlin PJ, Allshire RC. Methylation: lost in hydroxylation? *EMBO Rep*. 2005; 6:315–320.
32. Fodor BD, Kubicek S, Yonezawa M, O'Sullivan RJ, Sengupta R, Perez-Burgos L, Opravil S, Mechtler K, Schotta G, Jenuwein T. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. *Genes Dev*. 2006; 20:1557–1562.
33. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. *Nature*. 2006; 442:312–316.
34. Karytinis A, Forneris F, Profumo A, Ciossani G, Battaglioli E, Binda C, Mattevi A. A novel mammalian flavin-dependent histone demethylase. *J Biol Chem*. 2009; 284:17775–17782.
35. Klose RJ, Kallin EM, Zhang Y. JmJC-domain-containing proteins and histone demethylation. *Nat Rev Genet*. 2006; 7:715–727.
36. Shin S, Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. *Biochem Biophys Res Commun*. 2007; 359:742–746.

37. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. *Nat Rev Mol Cell Biol.* 2012; 13:297–311.
38. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. *Nat Rev Genet.* 2012; 13:343–357.
39. Luo W, Chang R, Zhong J, Pandey A, Semenza GL. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. *Proc Natl Acad Sci USA.* 2012; 109:3367–3376.
40. Wysocka J, Swigut T, Xiao H, Milne TA, Kwon SY, Landry J, Kauer M, Tackett AJ, Chait BT, Badenhorst P, Wu C, Allis CD. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. *Nature.* 2006; 442:86–90.
41. Kim TD, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ilnat MA, Li PK, Janknecht R. Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. *Am J Transl Res.* 2014; 6:236–247.
42. Kupershmit I, Khoury-Haddad H, Awwad SW, Guttman-Raviv N, Ayoub N. KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis. *Nucleic Acids Res.* 2014; 42:6168–6182.
43. Shin S, Janknecht R. Diversity within the JMJD2 histone demethylase family. *Biochem Biophys Res Commun.* 2007; 353:973–977.
44. Jung ES, Sim YJ, Jeong HS, Kim SJ, Yun YJ, Song JH, Jeon SH, Choe C, Park KT, Kim CH, Kim KS. Jmjd2C increases MyoD transcriptional activity through inhibiting G9a-dependent MyoD degradation. *Biochim Biophys Acta.* 2015; 1849:1081–1094.
45. Yang ZQ, Imoto I, Fukuda Y, Pimkhaokham A, Shimada Y, Imamura M, Sugano S, Nakamura Y, Inazawa J. Identification of a novel gene, GASC1, within an amplicon at 9p23–24 frequently detected in esophageal cancer cell lines. *Cancer Res.* 2000; 60:4735–4739.
46. Helias C, Struski S, Gervais C, Leymarie V, Mauvieux L, Herbrecht R, Lessard M. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. *Cancer Genet Cytogenet.* 2008; 180:51–55.
47. Rui L, Emre NC, Kruhlik MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, et al. Cooperative epigenetic modulation by cancer amplicon genes. *Cancer Cell.* 2010; 18:590–605.
48. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, Ra YS, Zilberberg K, McLeod J, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. *Nat Genet.* 2009; 41:465–472.
49. Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T. Genetic alterations and changes in expression of histone demethylases in prostate cancer. *Prostate.* 2010; 70:889–898.
50. Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino R, Wicha MS, Ethier SP, Yang ZQ. Identification and functional analysis of 9p24 amplified genes in human breast cancer. *Oncogene.* 2012; 31:333–341.
51. Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. *Cancer Res.* 2013; 73:2936–2942.
52. Matthews LC, Berry AA, Morgan DJ, Poolman TM, Bauer K, Kramer F, Spiller DG, Richardson RV, Chapman KE, Farrow SN, Norman MR, Williamson AJ, Whetton AD, et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy. *Proc Natl Acad Sci USA.* 2015; 112:5479–5484.
53. Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, et al. Progesterone receptor modulates ER α action in breast cancer. *Nature.* 2015; 523:313–317.
54. Ibrahim AA, Schmithals C, Kowarz E, Köberle V, Kakoschky B, Pleli T, Kollmar O, Nitsch S, Waidmann O, Finkelmeier F, Zeuzem S, Korf HW, Schmid T, et al. Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1 α and Epithelial-Mesenchymal Transition. *Clin Cancer Res.* 2017; <https://doi.org/10.1158/1078-0432.CCR-16-1762>.
55. Hong Q, Yu S, Yang Y, Liu G, Shao Z. A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer. *Oncotarget.* 2014; 5:4779–4787. <https://doi.org/10.18632/oncotarget.2029>.
56. Zhao L, Chang DW, Gong Y, Eng C, Wu X. Measurement of DNA damage in peripheral blood by the γ -H2AX assay as predictor of colorectal cancer risk. *DNA Repair (Amst).* 2017; 53:24–30.
57. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the γ -H2AX assay to monitor DNA damage and repair in translational cancer research. *Cancer Lett.* 2012; 327:123–133.
58. Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP, Yang ZQ. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. *Oncogene.* 2009; 28:4491–4500.
59. Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T, Yang ZQ. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. *Am J Cancer Res.* 2015; 5:1519–1530.
60. Jansen VM, Bholra NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV,

- Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, et al. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. *Cancer Res.* 2017; 77:2488–2499.
61. Jin L, Chun J, Pan C, Alesi GN, Li D, Magliocca KR, Kang Y, Chen ZG, Shin DM, Khuri FR, Fan J, Kang S. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis. *Oncogene.* 2017; <https://doi.org/10.1038/onc.2017.6>.
 62. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, Meng W, Zhou Q. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. *Cancer Res.* 2010; 70:2728–2738.
 63. Ooi AT, Gomperts BN. Molecular Pathways: Targeting Cellular Energy Metabolism in Cancer via Inhibition of SLC2A1 and LDHA. *Clin Cancer Res.* 2015; 21: 2440–2444.
 64. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. *Cancer Res.* 2006; 66:11341–11347.
 65. Wissmann M, Yin N, Müller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R, Metzger E, Schüle R. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent geneexpression. *Nat Cell Biol.* 2007; 9:347–353.
 66. Hamada S, Suzuki T, Mino K, Koseki K, Oehme F, Flamme I, Ozasa H, Itoh Y, Ogasawara D, Komarashi H, Kato A, Tsumoto H, Nakagawa H, et al. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. *J Med Chem.* 2010; 53:5629–5638.
 67. Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ, Ratcliffe PJ. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1 α . *Biochem J.* 2008; 416:387–394.
 68. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. *Oncogene.* 2010; 29:625–634.
 69. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. *J Cell Mol Med.* 2009; 13:2780–2786.
 70. Semenza G. Hypoxia-inducible factors in physiology and medicine. *Cell.* 2012; 148:399–408.
 71. Lee HY, Yang EG, Park H. Hypoxia enhances the expression of prostate-specific antigen by modifying the quantity and catalytic activity of Jumonji C domain-containing histone demethylases. *Carcinogenesis.* 2013; 34:2706–2715.
 72. Li X, Dong S. Histone demethylase JMJD2B and JMJD2C induce fibroblast growthfactor 2: mediated tumorigenesis of osteosarcoma. *Med Oncol.* 2015; 32:53.
 73. Nakayama F, Umeda S, Yasuda T, Fujita M, Asada M, Meineke V, Imamura T, Imai T. Cellular internalization of fibroblast growth factor-12 exerts radioprotective effects on intestinal radiation damage independently of FGFR signaling. *Int J Radiat Oncol Biol Phys.* 2014; 88:377–384.
 74. Feng S, Zhou L, Nice EC, Huang C. Fibroblast growth factor receptors: multifactorial-contributors to tumor initiation and progression. *Histol Histopathol.* 2015; 30:13–31.
 75. Arteaga MF, Mikesch JH, Qiu J, Christensen J, Helin K, Kogan SC, Dong S, So CW. The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. *Cancer Cell.* 2013; 23:376–389.
 76. Cheung N, Fung TK, Zeisig BB, Holmes K, Rane JK, Mowen KA, Finn MG, Lenhard B, Chan LC, So CW. Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia. *Cancer Cell.* 2016; 29:32–48.
 77. Agger K, Miyagi S, Pedersen MT, Kooistra SM, Johansen JV, Helin K. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells. *Genes Dev.* 2016; 30:1278–1288.
 78. Vinatzer U, Gollinger M, Müllauer L, Raderer M, Chott A, Streubel B. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. *Clin Cancer Res.* 2008; 14:6426–6431.
 79. Kim TD, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ihnat MA, Li PK, Janknecht R. Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors. *Am J Transl Res.* 2014; 6:236–247.
 80. Kim TD, Shin S, Berry WL, Oh S, Janknecht R. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. *J Cell Biochem.* 2012; 113:1368–1376.
 81. Xu Y, Yao H, Jin Y, Ma Y, Wang H, Shao Q. Expression of Jumonji domain containing protein 2C and hypoxia-inducible factor-1 α in gastric carcinoma and their clinical significance. *Natl Med J China.* 2013; 93:3375–3378.
 82. Li N, Jiang D. Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer. *Biomed Pharmacother.* 2017; 89:305–315.
 83. Rose NR, Woon EC, Kingham GL, King ON, Mecinović J, Clifton IJ, Ng SS, Talib-Hardy J, Oppermann U, McDonough MA, Schofield CJ. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. *J Med Chem.* 2010; 53:1810–1818.
 84. Tan H, Wu S, Wang J, Zhao ZK. The JMJD2 members of histone demethylase revisited. *Mol Biol Rep.* 2008; 35: 551–556.
 85. Hamada S, Kim TD, Suzuki T, Itoh Y, Tsumoto H, Nakagawa H, Janknecht R, Miyata N. Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji

- C-domain-containing histone lysine demethylase inhibitors. *Bioorg Med Chem Lett*. 2009; 19:2852–2855.
86. Ayrapetov MK, Gursoy-Yuzugullu O, Xu C, Xu Y, Price BD. DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. *Proc Natl Acad Sci USA*. 2014; 111:9169–9174.
87. Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR, Price BD. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. *Nat Cell Biol*. 2009; 11:1376–1382.
88. Suzuki T, Miyata N. Lysine demethylases inhibitors. *J Med Chem*. 2011; 54:8236–8250.
89. Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M. The role of histone demethylases in cancer therapy. *Mol Oncol*. 2012; 6:683–703.
90. Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, Yamauchi T, Waters NJ, Olhava EJ, Pollock RM, Smith JJ, Copeland RA, Blakemore SJ, Bernt KM, et al. Mechanisms of Pinometostat (EPZ-5676) Treatment Emergent Resistance in MLL Rearranged Leukemia. *Mol Cancer Ther*. 2017; 16:1669–1679.